Biodexa Completes Recruitment Of Cohort A In Study Of MTX110 In Patients With Recurrent Glioblastoma
Portfolio Pulse from Benzinga Newsdesk
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) has completed recruitment for cohort A of its Phase 1 study of MTX110 in patients with recurrent glioblastoma. The study is designed to assess the feasibility and safety of intermittent infusions of MTX110. The company plans to commence enrolment for cohort B upon approval by the study's Data Safety Monitoring Board, expected by the end of October 2023. Biodexa also plans to add two more investigational centres into the study by January 2024.
October 03, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biodexa's completion of recruitment for cohort A of its MTX110 study marks a significant milestone in the company's clinical development. The upcoming enrolment for cohort B and the addition of two more investigational centres could potentially accelerate the study's progress.
The completion of recruitment for cohort A signifies progress in Biodexa's clinical development, which could positively impact investor sentiment. The upcoming enrolment for cohort B and the addition of more investigational centres could potentially accelerate the study's progress, further boosting investor confidence in the company's ability to execute its clinical development plans.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100